Symbol
|
AFOBIL | UZPLTQ | ZMABQV | LCDMLK | YVALTQ | Z09BLZ | ZYSLTQ | AAJPTQ | MBQZJB | MAEWJB | LKVCLK | MAMMJB | MCBJJB | MCBVJB | MCCJJB | ACPDTQ | ACPETQ | CTBBKB |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nom | Barrier Express Certificate | Express Certificate with European Knock-In | Express Voncert | LUKB Autocallable Multi Barrier Reverse Convertible | Express Certificate | Express Note* | Express Certificate with European Knock-In | Express Certificate with European Knock-In | Multi Express Certifikat with European Knock-In | Express Certificate | LUKB Autocallable Multi Barrier Reverse Convertible | Multi Express Certifikat with European Knock-In | Multi Express Certifikat with European Knock-In | Multi Express Certifikat with European Knock-In | Multi Express Certifikat with European Knock-In | Express Certificate with European Knock-In | Express Certificate with European Knock-In | Barrier Express Certificate |
Sous-jacent
|
Bouygues S.A. / Roche AG | Amgen Inc. / Novartis Sandoz Basket / Novo Nordisk AS (B) / Pfizer Inc. / Roche AG | Nestlé S.A. / Novartis Sandoz Basket / Roche AG | Nestlé / Roche GS | Johnson & Johnson / Nestlé S.A. / Roche AG / Swiss RE AG | Nestlé / Roche GS / Swisscom | Baloise N / Compagnie Financière Richemont SA / Julius Baer Group / Lonza Group N / Nestlé S.A. / Novartis AG / Partners Group Hldg. AG / Roche AG / Sika AG / UBS Group AG | Baloise N / Compagnie Financière Richemont SA / Julius Baer Group / Lonza Group N / Nestlé S.A. / Novartis AG / Partners Group Hldg. AG / Roche AG / Sika AG / UBS Group AG | Nestlé / Novartis / Roche GS | Nestlé / Novartis / Roche GS | Nestlé / Novartis / Roche GS | Nestlé / Novartis / Roche GS / UBS / Zurich | Nestlé N / Novartis N / Roche GS / Swisscom N / Zurich Insurance Group AG | Nestlé N / Novartis N / Roche GS / Swisscom N / Zurich Insurance Group AG | Nestlé N / Novartis N / Roche GS / Swisscom N / Zurich Insurance Group AG | Nestlé / Novartis / Roche GS / UBS / Zurich | Nestlé / Novartis / Roche GS / UBS / Zurich | Lonza / Novartis / Roche GS |
Emetteur
|
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Échéance
|
20.07.2027 | 22.09.2025 | 16.03.2026 | 16.10.2026 | 24.03.2028 | 25.03.2027 | 27.05.2025 | 15.01.2026 | 29.01.2027 | 13.02.2026 | 18.06.2026 | 27.09.2027 | 03.04.2028 | 03.04.2028 | 03.04.2028 | 10.04.2029 | 10.04.2029 | 11.04.2028 |
Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Prix d'exercise
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Demande | 84,72 | 46,910 | - | - | 82,79 | - | 101,35 | 94,05 | - | - | - | - | - | - | - | 98,66 | 98,87 | 103,37 |
Offre | - | 0,490 | - | - | 83,59 | - | - | - | - | - | - | - | - | - | - | 99,46 | 99,67 | 104,20 |